Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

YouTube video by Born Celtic

Kazia Therapeutics has been awarded 'Drug Discovery Company of the Year' in the 2026 BioTech Breakthrough Awards for its innovative cancer therapies.

The webcast is scheduled for 8:30 a.m. Eastern on Nov. 9; Kazia management will also be available for one-on-one meetings during the Boston conference.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd., a biotechnology company specializing in central […]

Key Points Kazia Therapeutics dosed the first patient in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent or progressive AT/RT. The

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, […]

Kazia Therapeutics (NASDAQ: KZIA) reported new preclinical and translational data showing its PI3K/mTOR inhibitor paxalisib reduced tumor burden by 52% (p=0.035) in a microsatellite stable / proficient mismatch repair (MSS/pMMR) colorectal cancer model. In a separate study, adding paxalisib to an existing checkpoint inhibitor immunotherapy cut tumor volume by an additional 50% versus immunotherapy alone (p=0.022). Across both models, treatment was well tolerated with no treatment-related toxicity observed.Kazia is also running a next-generation biomarker program to define molecular, immune and epigenetic signatures linked to paxalisib response, and has filed a new patent related to colorectal cancer use. The company plans a five-arm Phase 2 trial in pre-treated MSS/pMMR metastatic colorectal cancer, testing paxalisib monotherapy and combinations with pembrolizumab versus standard of care. The primary endpoint will be safety and tolerability, with key efficacy endpoints as secondary measures. Enrollment is expected to start in Q1 2027, with full enrollment of all five arms targeted by year-end 2027.

Kazia Therapeutics (NASDAQ: KZIA) closed an oversubscribed, tranched registered public offering generating approximately $40 million in upfront gross proceeds from the sale of 2,580,000 ADSs (or pre‑funded warrants) at a combined public offering price of $15.50 per ADS with accompanying Series A and Series B warrants. The clinical milestone‑linked warrants are exercisable immediately at premiums to the ADS price: Series A at $17.825 per ADS (15% premium) for up to 2,243,478 ADSs, tied to Stage IV TNBC data expected in 2H 2027, and Series B at $19.375 per ADS (25% premium) for up to 2,064,000 ADSs, tied to HR+/HER2‑ data expected in 1H 2028. If fully exercised, total potential gross proceeds from the Offering would be about $120 million. Kazia plans to use net proceeds primarily to fund clinical development of paxalisib in triple‑negative breast cancer, HR+/HER2‑ breast cancer, and pMMR colorectal cancer, and for working capital and general corporate purposes. The company will host a corporate update call on September 1, 2026 at 8:00am ET.

SYDNEY, Aug. 28, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at a purchase price of $17.825 per ADS and will expire upon the earlier of 30 days following the Company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase up to 2,064,000 ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at a purchase price of $19.375 per ADS and will expire upon the earlier of 30 days following the Company's HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance.

SYDNEY, Aug. 27, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the "Offering") of (i) American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at an exercise price equal to 115% of the initial public offering price per ADS and accompanying Warrants and expire upon the earlier of 30 days following the Company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at an exercise price equal to 125% of the initial public offering price per ADS and accompanying Warrants and expire upon the earlier of 30 days following the Company's HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today...

Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, Aug. 27, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer (TNBC).

SYDNEY, Aug. 28, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the “Offering”) of (i) 2,580,000 American Depositary Shares (“ADSs”), each representing […]

Kazia Therapeutics (NASDAQ: KZIA) has commenced a tranched registered public offering of American Depositary Shares (ADSs), each representing 500 ordinary shares, or pre-funded warrants in lieu of ADSs, together with accompanying Series A and Series B warrants to purchase ADSs (or pre-funded warrants).The Series A warrants are immediately exercisable at 115% of the initial offering price and expire on the earlier of 30 days after the Stage IV triple-negative breast cancer data readout, expected in 2H 2027, or five years from issuance. Series B warrants are exercisable at 125% of the initial offering price and expire on the earlier of 30 days after the HR+/HER2- breast cancer data readout, expected in 1H 2028, or five years from issuance. According to Kazia, all securities are being sold by the company, and net proceeds are intended primarily to fund clinical development of paxalisib and for working capital and general corporate purposes. The size and final terms of the offering remain subject to market and other conditions.

Kazia Therapeutics (NASDAQ: KZIA) reported initial data from six evaluable Stage IV triple-negative breast cancer (TNBC) patients treated with its lead asset, paxalisib, in an ongoing Phase 1b trial combining paxalisib with pembrolizumab and chemotherapy. All six patients achieved clinical benefit, yielding a 100% clinical benefit rate. Five patients achieved an objective response (one complete, four partial), for an 83% objective response rate, and one patient had stable disease. A 44-year-old woman achieved a complete metabolic response with no evidence of disease since November 2025. No paxalisib-related serious adverse events were reported, and no grade 3 or higher hyperglycemia, stomatitis or mucositis were observed.Translational analyses showed median reductions of 83% in circulating tumor cell clusters within six to seven weeks and 51% in terminally exhausted CD8+ T cells within about three weeks, with preserved total CD8+ T cell counts and blood-based evidence of improved immune function. Enrollment in the Phase 1b study is expected to complete by July 2027, with interim updates anticipated throughout 2026 and 2027.

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that...